Market Overview

UPDATE: Bank of America Upgrades Seattle Genetics On Trial Risks


In a report published Tuesday, Bank of America analyst Steve Byrne upgraded the rating on Seattle Genetics (NASDAQ: SGEN) from Underperform to Neutral, but lowered the price target from $46.00 to $40.00.

In the report, Bank of America noted, “We rate SGEN shares Neutral. While we believe expectations for Adcetris' label expansions are mostly priced in, given the stock's pull-back and potential favorable AETHERA readout in 2H14 we rate SGEN shares Neutral. SGEN's ADC platform could add upside to valuation but these wholly owned products are in early stage development.”

Seattle Genetics closed on Monday at $35.10.

Latest Ratings for SGEN

Oct 2020Morgan StanleyMaintainsEqual-Weight
Oct 2020SVB LeerinkMaintainsOutperform
Oct 2020B of A SecuritiesMaintainsNeutral

View More Analyst Ratings for SGEN
View the Latest Analyst Ratings


Related Articles (SGEN)

View Comments and Join the Discussion!

Posted-In: Bank of America Steve ByrneAnalyst Color Upgrades Analyst Ratings

Latest Ratings

THOWedbushInitiates Coverage On107.0
WGOWedbushInitiates Coverage On67.0
WLLMKM PartnersInitiates Coverage On30.0
ABNBAtlantic EquitiesInitiates Coverage On75.0
PGRKeefe, Bruyette & WoodsUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at